Key takeaways
Rybelsus (semaglutide) and Ozempic (semaglutide) are both medications used to treat Type 2 diabetes and belong to the glucagon-like peptide-1 (GLP-1) receptor agonist class. They share the same active ingredient, semaglutide, and can help lower blood sugar levels. However, they differ in their form and dosing. Rybelsus is an oral tablet taken once daily, while Ozempic is a subcutaneous (under the skin) injection given once a week. Both Rybelsus and Ozempic are only available as brand-name medications. Both can cause side effects like nausea, vomiting, and diarrhea. Additionally, Ozempic is FDA-approved to lower the risk of heart attack, stroke, and death in adults with Type 2 diabetes and heart disease, an indication not shared by Rybelsus. Both medications carry a risk of thyroid cancer and should not be used if you have a personal or family history of certain thyroid cancers.
